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Abstract
Background: Monocytes, their progeny such as dendritic cells and osteoclasts and products
including tumor necrosis factor (TNF)-α, interleukin (IL)-1α and IL-1β play important roles in
cancer, inflammation, immune response and atherosclerosis. We previously showed that mactinin,
a degradative fragment of the cytoskeletal protein α-actinin, is present at sites of monocytic
activation in vivo, has chemotactic activity for monocytes and promotes monocyte/macrophage
maturation. We therefore sought to determine the mechanism by which mactinin stimulates
monocytes.
Results: Radiolabeled mactinin bound to a heterocomplex on monocytes comprised of at least 3
proteins of molecular weight 88 kD, 79 kD and 68 kD. Affinity purification, mass spectroscopy and
Western immunoblotting identified heat shock protein (Hsp)-90 as the 88 kD component of this
complex. Hsp90 was responsible for mediating the functional effects of mactinin on monocytes,
since Hsp90 inhibitors (geldanamycin and its analogues 17-allylamino-17-demethoxygeldanamycin
[17-AAG] and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin [17-DMAG]) almost
completely abrogated the stimulatory activity of mactinin on monocytes (production of the pro-
inflammatory cytokines IL-1α, IL-1β and TNF-α, as well as monocyte chemotaxis).
Conclusion: Mactinin is a novel inducer of Hsp90 activity on monocytes and may serve to
perpetuate and augment monocytic activation, thereby functioning as a "matrikine." Blockage of this
function of mactinin may be useful in diseases where monocyte/macrophage activation and/or
Hsp90 activity are detrimental.
Background
Cell migration and chemotaxis that occur in malignancies
and inflammatory processes may deposit the focal adhe-
sion component α-actinin in their migratory path [1]. We
previously showed that extracellular α-actinin is degraded
by monocyte-secreted urokinase to generate a specific
fragment (which we named mactinin) [2]. Mactinin is
found at various sites of monocytic activation in vivo [2-
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4], has chemotactic activity for monocytes [4] and pro-
motes monocyte/macrophage maturation [5]. These find-
ings suggest that mactinin is a functionally important
mediator of monocytic activity.
Monocytes and macrophages play pivotal roles during
inflammatory and immune processes by releasing various
cytokines including tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1α and IL-1β, chemokines, enzymes and other
factors [6]. In some disease processes such as infections
[6] and wound healing [3,7,8], macrophage activity may
be beneficial in promoting healing. In other diseases, such
as arthritis [9-13] and atherosclerosis [14,15], macro-
phage activation may contribute to pathogenesis and
propagation. The monocyte/macrophage system also
plays an integral role in malignancies by secretion of these
cytokines, generation of dendritic cells and osteoclasts
and modulation of the immune response [reviewed in
[16,17]].
In the current study, we examined the mechanism medi-
ating the stimulatory effect of mactinin on monocytes. We
show here that mactinin binds to a heterocomplex includ-
ing heat shock protein (Hsp)-90 on monocytes, and that
Hsp90 is critically important for the stimulatory activity of
mactinin on monocytes since inhibition of Hsp90 almost
completely blocked mactinin-induced cytokine produc-
tion and migration of monocytes. Hsp90 is a molecular
chaperone whose activity promotes chemotaxis, migra-
tion, proliferation and cytokine secretion in malignant
and endothelial cells and in monocytes [18-28]. Our iden-
tification of mactinin as a novel inducer of Hsp90 activity
on monocytes therefore has important implications for
diverse conditions including malignancies, autoimmune
disease, inflammation and atherosclerosis.
Results
Mactinin stimulates IL-1α, IL-1β and TNF-α production by 
monocytes
Peripheral blood monocytes were isolated and cultured
for 24 h with 100 nM mactinin, 100 nM α-actinin, 10 nM
GST or medium alone (no treatment). The GST condition
was included in order to control for the 10% contaminat-
ing GST in our mactinin preparation. Supernatants were
recovered and centrifuged to remove nonadherent cells
and aliquots assayed for the 3 cytokines. As shown in Fig.
1, the levels of IL-1α, IL-1β, and TNFα were significantly
increased in the supernatants of mactinin-treated mono-
cytes. Control cultures treated with α-actinin or GST did
not show any increase in cytokine production. Mactinin
did not stimulate the production of granulocyte macro-
phage colony-stimulating factor (GM-CSF), interferon
(IFN)-α, IL-12, macrophage colony-stimulating factor (M-
CSF), or macrophage inhibitory protein (MIP)-1α (not
shown). These findings indicate that mactinin directly
stimulates the production of specific pro-inflammatory
cytokines from monocytes.
Mactinin binds to monocytes
To assess whether mactinin binds to peripheral blood
monocytes, these cells were incubated with or without
mactinin and then stained with antiserum to mactinin or
isotype matched (IgG1) control pre-immune antiserum.
Bound mactinin was measured using flow cytometry (Fig.
2A). There was a significantly higher percentage of posi-
tively staining monocytes that had been incubated with
mactinin (44 ± 2%; Fig 2A plot 3) than monocytes not
incubated with mactinin (15 ± 1%; p = 0.003; Fig 2A plot
1) or monocytes incubated with mactinin but detected
with control IgG1 antiserum (22% ± 1%; p = 0.005; Fig 2A
plot 2). Furthermore, the mean fluorescence intensity of
monocytes incubated with mactinin (509 ± 2%) was sig-
nificantly higher than that of monocytes incubated with-
out mactinin (265 ± 1%; p < 0.0001) or monocytes
incubated with mactinin but detected with control IgG1
antiserum (388 ± 4; p < 0.002). We saw a similar increase
in positive staining and mean fluorescence in HL-60 cells
incubated with mactinin (data not shown). Thus, mac-
tinin binds to both monocytes and monocytoid cells.
Mactinin binds to a specific high molecular weight 
complex on HL-60 cells
We next examined the specificity of mactinin binding to
HL-60 cells, by determining the ability of excess unlabeled
(cold) mactinin to compete for the binding of [125I]mac-
tinin to HL-60 cells. HL-60 cells were pre-incubated with
or without unlabeled mactinin, followed by addition of
[125I]mactinin. Autoradiography of the clarified lysates
Mactinin stimulates production of cytokines from monocytes Figure 1
Mactinin stimulates production of cytokines from 
monocytes. Human peripheral blood monocytes were incu-
bated for 24 hrs with 100 nM mactinin, 100 nM α-actinin, 10 
nM glutathione-S-transferase (GST), or no treatment. The 
concentrations of the indicated cytokines were determined 
in the supernatant. UD: undetectable at an assay sensitivity of 
1.0 pg/ml. Data is shown as the mean +/- SEM. N = 3–4. Sig-
nificance of differences between no treatment and mactinin: 
*P < 0.01.BMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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Mactinin binds to a Hsp90 containing complex on the surface of monocytoid cells Figure 2
Mactinin binds to a Hsp90 containing complex on the surface of monocytoid cells. A: Mactinin binds directly to 
peripheral blood monocytes. Monocytes incubated without (plot 1) or with (plot 3: shaded area) 100 nM mactinin were 
analyzed by flow cytometry to detect mactinin bound to the cell surface. The control condition (cells incubated with mactinin 
and stained with isotype matched IgG1 antiserum) is shown in plot 2. One of four representative experiments is shown. B: 
Mactinin binds specifically in a high molecular weight complex on monocytoid HL-60 cells. HL-60 cells were pre-
incubated with or without excess unlabeled (cold) mactinin, and then with [125I]mactinin. Cell lysate was resolved by 12% SDS-
PAGE under non-reducing conditions, and [125I]mactinin detected using autoradiography. Lane 1: high molecular weight com-
plex on cells incubated with [125I]mactinin alone. Lane 2: marked reduction in bound [125I]mactinin in cells pre-incubated with 
unlabeled mactinin. C: Mactinin binds to monocytoid HL-60 cells. HL-60 cells were biotinylated and then incubated for 1 
h at 4°C with 100 nM [125I]-mactinin, washed, and incubated without or with the cross-linkers DSP or BS3, lysed, and resolved 
by 6–20% gradient SDS-PAGE under non-reducing or reducing conditions. Lane 1: 31 kD radiolabeled mactinin alone, reducing 
conditions (no cells). Lane 2: radiolabeled mactinin bound to a high molecular weight complex on HL-60 cells, non-reducing 
conditions, no cross-linker. Lane 3: retention of most of the radiolabeled mactinin in the complex in presence of the imperme-
able, non-cleavable cross-linker BS3, reducing conditions. Lane 4: 31 kD radiolabeled mactinin separated from the binding com-
plex under reducing conditions, cleavable cross-linker DSP. Lane 5: retention of nearly all of the radiolabeled mactinin in the 
complex in presence of the cross-linker DSP, non-reducing conditions. D: Mactinin binds to 3 distinct proteins on HL-60 
cells. HL-60 cells were biotinylated (to detect cell surface proteins that bind to mactinin) and incubated with 100 nM mactinin. 
The HL-60 cell protein-mactinin complex (the material in lane 5 in Fig. 2C) was electroeluted, reduced, run over a mactinin 
column, and the bound proteins were resolved by 6–20% gradient SDS-PAGE. Biotinylated HL-60 proteins (88, 79 and 68 kD) 
that bound to the mactinin affinity column were detected by Western immunoblotting. E: Identification of Hsp90 in the 
mactinin-binding complex. The membrane shown in Fig. 2D was stripped and re-probed using an anti-Hsp90 antibody. A 
single 90 kD band was detected (lane 1). Recombinant Hsp90 was run in lane 2.BMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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resolved by 12% non-reducing SDS-PAGE detected a high
molecular weight complex on cells that were incubated
with [125I]mactinin (Fig. 2B, lane 1). This complex was
markedly reduced in cells pre-incubated with unlabeled
mactinin (Fig. 2B, lane 2). These results suggest that mac-
tinin can compete for a specific and potentially saturable
binding site on HL-60 cells.
Mactinin binds a hetero-complex of HL-60 cell membrane 
proteins including Hsp90
Mactinin has in vitro maturation promoting effects on
both monocytes and HL-60 leukemia cells [5]. We there-
fore elected to use the plentiful HL-60 cell line for bio-
chemical analysis of mactinin binding proteins. Biotin
surface labeled HL-60 cells were incubated with 100 nM
[125I]mactinin in the presence or absence of the cleavable,
cell-permeable cross-linker DSP or the non-cleavable, cell-
impermeable cross-linker BS3. The cells were lysed, centri-
fuged and proteins in the supernatant resolved by 6–20%
gradient SDS-PAGE under reducing or non-reducing con-
ditions. Autoradiography detected the 31 kD [125I]mac-
tinin that was bound to HL-60 cells in the absence of a
cross-linker (Fig. 2C, lane 2). Use of the cross-linker DSP
demonstrated that most of the [125I]mactinin bound to a
high molecular weight complex on HL-60 cells (Fig. 2C,
lane 5). Under reducing conditions, the free [125I]mac-
tinin could be separated out completely from the HL-60
protein complex seen with DSP (Fig. 2C, lane 4). Since
BS3 is not cleavable, the complex remained unchanged
(with bound [125I]mactinin) under reducing conditions
with BS3 (Fig. 2C, lane 3).
To identify HL-60 proteins in the binding complex, the
radiolabeled complex (from Fig. 2C, lane 5) was cut, elec-
troeluted, dialyzed, reduced with DTT, run on a column of
mactinin covalently bound to an Affi-Gel 15 matrix and
eluted to select for mactinin-binding proteins. A purifica-
tion step was necessary since mass spectrometry analysis
of the resulting proteins from the unpurified complex
showed many co-migrating proteins including myeloper-
oxidase, glucose-regulated protein 94, 78 kD glucose-reg-
ulated protein, calnexin, calreticulin precursor, moesin,
Hsc70-ps1, protein disulfide isomerase-associated 4, pro-
lyl 4-hydroxylase beta subunit and protein disulfide iso-
merase-associated 3 precursor. Nevertheless, even in the
unpurified complex, more peptides matched Hsp90 (27%
of all the peptides) than any other single protein.
The biotin-labeled HL-60 proteins that were eluted from
matrix-bound mactinin were separated by SDS-PAGE and
transferred to a PVDF membrane for detection of the pro-
teins by Western immunoblotting for biotin. As shown in
Fig. 2D, three protein bands of molecular weight 88, 79
and 68 kD were detected. A companion gel lane stained
with Coomassie-blue visualized only the 88 kD band (not
shown).
The identity of the 88 kD protein was confirmed by West-
ern immunoblotting. Re-probing the membrane shown
in Fig. 2D with antiserum to Hsp90 detected a single band
of 88 kD (Fig. 2E, lane 1), as well as recombinant Hsp90
run in a separate lane as a positive control (Fig. 2E, lane
2). Together, the above data indicate that mactinin binds
to a high molecular weight complex of at least 3 proteins
on monocytoid HL-60 cells, and one of these proteins is
Hsp90.
Hsp90 mediates the stimulation of monocytes by mactinin
To determine if Hsp90 identified in the mactinin-binding
complex is functionally involved in the activity of mac-
tinin on monocytes, we assessed the effect of 3 separate
Hsp90 inhibitors on mactinin-induced monocyte migra-
tion [4] and cytokine production.
As shown in Fig. 3, all three Hsp90 inhibitors (geldan-
amycin, 17-allylamino-17-demethoxygeldanamycin [17-
AAG] and 17-(dimethylaminoethylamino)-17-demethox-
ygeldanamycin [17-DMAG], completely suppressed
monocyte chemotaxis, since the number of cells that
migrated towards mactinin in the presence of the Hsp90
inhibitors was comparable to the number of cells that
migrated in medium alone (without mactinin; negative
control). In contrast, fmlp-induced chemotaxis was not
inhibited. The concentrations of the Hsp90 inhibitors
tested included 100, 200, and 400 nM geldanamycin, 0.5
and 1 μM 17-AAG, and 100 nM 17-DMAG, based on pre-
vious reports of in vitro Hsp90 inhibition studies [29,30].
All concentrations significantly inhibited migration with-
out meaningful differences (not shown).
Finally, we examined if the same Hsp90 inhibitors block
mactinin-induced inflammatory cytokine production
from monocytes (Fig. 4). Each of the three Hsp90 inhibi-
tors completely blocked the production of IL-1α and IL-
1β from monocytes. In contrast, production of TNF-α was
not completely blocked since TNF-α levels in the presence
of the Hsp90 inhibitors were higher than in medium
alone, though it was markedly reduced compared to the
levels seen with mactinin stimulation.
Discussion
This study shows that mactinin induces Hsp90-mediated
monocyte activation resulting in stimulation of cytokine
secretion and migration. The recognition that degradative
products of cytoskeletal proteins may influence Hsp90
activity in target cells has important implications for
diverse conditions including malignancies, autoimmune
disease, inflammation and atherosclerosis. Our findings
also extend the current understanding of "matrikines,"BMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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proteolytically released extracellular matrix-derived bioac-
tive peptides that influence many types of cells and proc-
esses (reviewed in [31-33]).
Hsp90 is a highly conserved member of the group of
molecular chaperones, is usually cytosolic [34,35] but
may also be associated with lipid rafts in the cell mem-
brane [36,37]. Hsps are constitutively expressed but
enhanced in response to cellular stresses [38]. Their major
function appears to be to act as protein chaperones, facil-
itating folding, oligomeric assembly, transport to a partic-
ular subcellular compartment, or switching between
active and inactive protein conformation [39]. Hsp90 reg-
ulates many client proteins involved in signal transduc-
tion [40]. Other important functions include stimulation
of chemotaxis, migration, proliferation and cytokine
secretion in malignant and endothelial cells [18-22].
We show for the first time that Hsp90 is a functionally crit-
ical component of the mactinin-binding heterocomplex
on monocytic cells. Two other proteins of molecular
weight 68 and 79 kD found in this complex may possibly
represent other Hsps, since previous studies have shown
that Hsp90/70 forms a receptor complex in monocytes
and macrophages [36,41]. Many Hsps interact with com-
ponents of the actin cytoskeleton, perhaps modulating
the cytoskeletal response to stress [42]. It has been
reported that Hsp90 and Hsp100 bind actin [43], while
the smaller Hsp20 has been reported to associate with
both actin and α-actinin [44]. However, it is likely that the
direct binding of extracellular mactinin is to other (as yet
unidentified) protein(s) on the surface of HL-60 cells,
which then form a hetero-complex with Hsp90.
In monocytes/macrophages and related cells, Hsp90
potently induces TNF-α and IL-1β expression and activa-
tion [23-26] and cell cycling and differentiation [27]. The
Hsp-activated macrophage axis may also play an impor-
tant role in atherosclerosis [reviewed in [28]]. Inhibitors
of Hsp90, such as geldanamycin and its analogues, have
been used to identify Hsp90 substrates [40,45]. We found
that geldanamycin and two of its analogues markedly
inhibited mactinin-induced chemotaxis and cytokine pro-
duction. Their ability to inhibit chemotaxis was specific
for mactinin since they had no significant effect on fmlp-
induced chemotaxis. We also found that Hsp90 inhibitors
blocked mactinin-induced cytokine production from
monocytes, confirming that Hsp90 mediates the stimula-
tory activity of mactinin on monocytes.
Our results suggest that a cytoskeletal protein derivative
(mactinin) may propagate inflammation, in part, by stim-
ulating production of the pro-inflammatory cytokines IL-
1α, IL-1β and TNF-α. These two cytokines are elevated in
the serum and synovial fluid of patients with rheumatoid
arthritis, and both are capable of inducing joint damage in
experimental arthritis models [10]. The clinical efficacy of
agents that block these cytokines in ameliorating bone
and joint destruction in arthritis is now widely accepted
[11].
Hsp90 induces urokinase-type plasminogen activator
secretion [20] and urokinase secreted by activated mono-
cytes degrades α-actinin to generate mactinin [2]. It is
Mactinin-induced monocyte migration is blocked by Hsp90  Inhibitors Figure 3
Mactinin-induced monocyte migration is blocked by 
Hsp90 Inhibitors. Monocytes were incubated with medium 
alone or with one of 3 Hsp90 inhibitors (G: geldanamycin; A: 
17-AAG; D: 17-DMAG), prior to testing for mactinin-
induced or fmpl-induced (control) chemotaxis. In the 
absence of mactinin or fmlp, 1302 +/- 122 cells migrated (not 
shown). Mactinin-induced migration was significantly inhib-
ited by each of the Hsp90 inhibitors, whereas fmlp-induced 
migration was not. Data is shown as the mean +/- SEM. N = 
3. Significance of differences in migration in the presence vs 
absence of Hsp90 inhibitors: *P < 0.01.
Mactinin-induced production of cytokines from monocyts is  blocked by Hsp90 inhibitors Figure 4
Mactinin-induced production of cytokines from 
monocyts is blocked by Hsp90 inhibitors. Monocytes 
were incubated for 24 hrs with medium alone, mactinin alone 
or mactinin + one of 3 Hsp90 inhibitors (G: geldanamycin; A: 
17-AAG; D: 17-DMAG). The concentrations of the indicated 
cytokines were determined in the supernatant. UD: undetec-
table at an assay sensitivity of 1.0 pg/ml. Data is shown as the 
mean +/- SEM. N = 3–4. Significance of differences between 
mactinin alone and the other conditions: *P < 0.01.BMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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therefore possible that the binding and stimulation of
Hsp90 activity on monocytes by mactinin itself (shown in
the current study) may represent a positive feed-forward
loop that further amplifies the immune/inflammatory
response. We therefore speculate that agents that block
mactinin may provide a novel strategy for inhibiting
Hsp90 activity in diverse diseases.
Conclusion
We have identified that Hsp90 mediates the stimulation
of monocytes by mactinin, a fragment of the cytoskeletal
protein α-actinin. Mactinin represents a novel inducer of
Hsp90 activity on monocytes. Our findings suggest that
inhibition of mactinin may be of benefit in diseases prop-
agated by monocyte/macrophage activation or Hsp90
activity.
Methods
Isolation of peripheral blood monocytes
Mononuclear cells were isolated from blood samples
obtained from healthy adult donors by density gradient
centrifugation over Histopaque 1077 (Sigma, St. Louis,
MO) as previously described [4]. Contaminating red cells
were lysed in distilled water and monocytes were isolated
using an LS separation column with a magnetic monocyte
isolation kit in accordance with the manufacturer's
instructions (Miltenyi Biotec, Auburn, CA). This negative
selection method yielded more than 90% monocytes, as
determined by CD14 expression, within three hours of
phlebotomy. These studies were approved by the Institu-
tional Review Board of the Minneapolis Veterans Affairs
Medical Center.
Cell Culture
HL-60 myeloid leukemia cells were purchased from the
American Type Culture Collection (Manassas, VA) and
maintained in RPMI medium with 50 μg/ml gentamicin
and 15% fetal calf serum at 37°C and 5% CO2. We have
previously reported that mactinin promotes monocytic
maturation in this cell line [5].
Source of mactinin
Dr. D.R. Critchley of the University of Leicester, U.K.
kindly provided a PGEX2 vector which encodes the actin-
binding domain, residues 2–269 of chicken smooth mus-
cle α-actinin, fused with the carboxy terminus of glutath-
ione S-transferase (GST) and containing an engineered
thrombin cleavage site [2]. Fusion protein was expressed
in Escherichia coli, and purified by affinity chromatogra-
phy on immobilized glutathione. The fusion protein was
then cleaved with thrombin (Calbiochem, San Diego, CA)
to produce the actin-binding domain of α-actinin and the
GST carrier. These products were then separated by
reverse-phase high-performance liquid chromatography
(HPLC) on a C-4 column. SDS-PAGE demonstrated that
the mactinin was more than 90% of the total protein of
pooled fractions, with the remaining 10% being GST. This
10–20 μM mactinin preparation from the C-4 column
assayed negative for endotoxin with a Pyrotell chromoge-
nic assay kit, which can detect 0.25 endotoxin units/ml
(Associates of Cape Cod, Woods Hole, MA). Mactinin
from the C-4 column was maintained in 30% acetonitrile
and diluted in fresh, pyrogen-free water or tissue culture
media for use in the various assays.
Mactinin Antiserum
Purified recombinant chicken mactinin was modified by
coupling with dinitrophenol and injected into two New
Zealand white rabbits along with complete Freund's adju-
vant, as described previously [2], to generate highly sensi-
tive mactinin antiserum. Boosts were performed with
peptide and incomplete Freund's adjuvant. These animal
studies were approved by the Institutional Animal Care
and Use Committee (IACUC). Antisera were screened,
and sera reacting to mactinin were immunoaffinity-puri-
fied over a column of recombinant mactinin covalently
bound to an Affi-Gel 15 matrix (Bio-Rad, Hercules, CA).
Measurement of cytokine production by monocytes
Cytokine levels in culture supernatants were determined
at the Cytokine Reference Lab (University of Minnesota)
by multiplex assay using the Luminex system (Austin, TX)
and human cytokine-specific bead sets (R&D Systems,
Minneapolis, MN) or ELISA kits (Bender Medsystems,
Burlingame, CA). Each set of experiments was repeated
two to three times.
Detection of binding of mactinin to monocytes using flow 
cytometry
Two million monocytes were incubated with or without
100 nM recombinant mactinin in PBS containing 0.5%
bovine serum for 90 min at 4°C with occasional mixing.
Monocytes were then washed and incubated with no
antiserum, control pre-immune rabbit IgG1 or affinity-
purified rabbit antiserum against recombinant mactinin
for 30 minutes at 4°C with occasional mixing, followed
by another wash and incubation with goat anti-rabbit
IgG-FITC (Sigma) for 30 min at 4°C in the dark with occa-
sional mixing. Stained cells were washed and analyzed
using a flow cytometer (Beckton Dickinson Model 450).
Radiolabeling of mactinin
Recombinant mactinin is relatively insoluble at pH > 5.5,
in the concentrations required for the labeling reaction.
We therefore radiolabeled the purified uncleaved recom-
binant fusion protein using the Bolton-Hunter reagent
(Perkin Elmer Life Science, Boston, MA) following the
manufacturer's specifications. Briefly, 250 μCi of Bolton-
Hunter reagent were dried with N2 gas and chilled on ice
and incubated with 1 mg recombinant fusion protein inBMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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150 μl 0.1 M KH2PO4, pH 8.5 at 0°C for 1 h and then at
4°C overnight. The reaction was terminated by adding
100 μl of 1% glycine followed by 100 μl of 0.04% phenol
red, and finally 100 μl of 0.01% gelatin, all in 0.1 M KH2,
PO4, pH 8.5 buffer. Then, iodinated fusion protein was
separated from free 125I by chromatography on a 10 ml
PD-10 column, (Amersham Biosciences, Uppsala, Swe-
den) equilibrated in 0.1 M KH2PO4, pH 8.5. Fractions
containing fusion protein were pooled, dialyzed against
100 volumes of 50 mM Tris, 150 mM NaCl, ph 7.4, (TBS)
with 2.5 mM CaCl2 overnight, and cleaved with thrombin
at a ratio of 1:250 (wt/wt) for 2 h at room temperature
(25°C). [125I]mactinin was separated from GST by reverse
phase C-4 HPLC as previously described [2].
Specificity of mactinin binding to HL-60 cells
HL-60 cells were incubated in RPMI medium with or
without 5 μM unlabeled (cold) mactinin for 30 min at
room temp. Then 100 nM [125I]mactinin was added and
the cells incubated at 37°C for 2 h. The cells were washed,
lysed, clarified by centrifugation, the supernatant resolved
by 12% SDS-PAGE under non-reducing conditions.
[125I]mactinin was detected using autoradiography using
Kodak BioMax MS film at -70°C.
Labeling of HL-60 cell surface proteins with biotin
Since mactinin promotes the maturation of HL-60 cells as
well as monocytes [5], and HL-60 cells are readily availa-
ble as suspension culture cells in unlimited numbers with
potentially several days of in vitro viability, they were used
instead of monocytes for the biochemical assays. HL-60
cells (120 × 106) were washed two times with PBS and
then diluted to 2 × 106 cells/ml in PBS. NHS-LC-biotin
(Pierce, Rockford, IL) was dissolved in DMSO and added
to HL-60 cells at a concentration of 0.1 mg/ml of cells
[46]. Samples were incubated at 4°C for 15 min and then
washed three times with PBS + 50 mM NH4Cl to remove
unbound biotin.
Cross-linking of mactinin bound to HL-60 cells
One hundred twenty million biotin-labeled HL-60 cells
were incubated with 100 nM [125I]mactinin for 1 h at 4°C
with occasional mixing. Cells were then washed and
resuspended in PBS. In some tubes, a membrane permea-
ble and thio-cleavable cross-linker, 1 mM dithiobis [suc-
cinimidyl-proprionate] (DSP, Pierce) was added for 1 h at
4°C. In other tubes, the membrane-impermeable and
non-cleavable cross-linker 1 mM bis(sulfosuccinimi-
dyl)suberate (BS3, Pierce) was added. The cross-linking
reaction was quenched with 20 mM Tris, pH 7.5 for 15
min at room temperature, the cells washed again with PBS
and lysed in 500 μl of 50 mM Tris, pH 7.8, 5 mM CaCl2,
1% Triton, 2 mM PMSF, 10 μM pepstatin A. The lysate was
centrifuged at 12,000 RPM for 10 min at 4°C, and the
supernatant was further analyzed as described below.
SDS-PAGE
Supernatant samples were concentrated using a speed-vac,
mixed with an equal volume of gel loading buffer and the
proteins resolved by 6–20% gradient SDS-PAGE. After
electrophoresis, the gel was cut, and some lanes were
dried and exposed to Kodak BioMax MS film at -70°C for
detection of [125I]mactinin. From companion lanes, gel
slices containing lysed HL-60 cells cross-linked to
[125I]mactinin were electroeluted, dialyzed against TBS,
concentrated and reduced with DTT, then run on a 5 ml
column of recombinant mactinin covalently bound to an
Affi-Gel 15 matrix. The material was loaded on the col-
umn, washed with 100 ml TBS, and eluted with 0.1 M
sodium citrate, 0.3 M NaCl, pH 3.0. Two ml fractions were
collected, neutralized with 2 M Tris, pooled and dialyzed
against 10 mM Tris, pH 7.5 at 4°C. The eluate was concen-
trated and proteins resolved by 6–20% gradient SDS-
PAGE under reducing conditions. After electrophoresis,
the gel was transferred to an Immuno-Blot PVDF mem-
brane (Bio-Rad). The membrane was blocked with 5%
BSA-TBS, 0.05% Tween-20 for 1 h at room temperature
with rocking, followed by incubation with 40 pg/ml
streptavidin-horseradish peroxidase (Pierce) in 5% BSA-
TBS, Tween for 1 h at room temperature with gentle rock-
ing. The membrane was washed 5 times in TBS-Tween,
and biotin-labeled proteins detected by SuperSignal West
Femto enhanced chemiluminescence (ECL) substrate
(Pierce) using the manufacturer's directions.
Mass spectrometry
SDS-PAGE gel slices corresponding to the biotin-labeled
proteins from the reduced high molecular weight complex
were analyzed using a Waters Q-Tof mass spectrometer at
the Keck Foundation Biotechnology Resource Laboratory
(New Haven, CT). Trypsin digestion was carried out on
the SDS-PAGE gel slices as previously described [5]. The
mass spectrometer data were searched using the auto-
mated Mascot algorithm.
Western immunoblotting
To further confirm the identity of the proteins in the mac-
tinin-binding complex identified by mass spectrometry,
biotin-labeled mactinin-binding proteins on the PVDF
membrane were washed 5 times with TBS-Tween to
remove the streptavidin-horseradish peroxidase and ECL
substrate. The membrane was then treated with antiserum
to Hsp90 (BD Bioscience), followed by alkaline phos-
phatase-conjugated secondary antibody (Sigma). Immu-
noreactive protein bands were detected by alkaline
phosphatase reaction using 5-bromo-4-chloro-3-indoyl
phosphate/nitroblue tetrazolium.
Treatment of monocytes with Hsp90 inhibitors
The Hsp90 inhibitors geldanamycin, 17-AAG and 17-
DMAG [31] (InvivoGen, San Diego, CA) were each dis-BMC Cell Biology 2009, 10:60 http://www.biomedcentral.com/1471-2121/10/60
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solved in DMSO to a stock solution of 2 mmol/L. They
were then diluted in RPMI media supplemented with 100
units/ml penicillin and 100 μg/ml streptomycin. After
treatment, monocytes were incubated with 0.2% trypan
blue and assayed for viability using light microscopy. The
percentage of viable cells, which exclude trypan blue, was
> 95% in all cultures.
Chemotaxis assay
Cell migration was assessed, as previously described [4],
in a 48-well micro chemotaxis chamber (NeuroProbe,
Gaithersburg, MD). One nM mactinin or 1 nM formyl-
methionyl-leucyl-phenylalanine (fmlp) was placed in the
lower compartment. Monocytes (30–35,000) were treated
for 30 min at 37°C with various Hsp90 inhibitors and
then placed in the upper compartment of the well. The
two compartments were separated by a 5-μm pore size
PVP-free polycarbonate filter. The chamber was incubated
for 90 min at 37°C in 5% CO2. At the end of the incuba-
tion period, the filter was removed, fixed, and stained
with a Hema 3 stain set (Fisher, Pittsburgh, PA). The
number of cells that migrated through the membrane
pore in three high-power fields (×400) was counted by
light microscopy. Three chamber membranes were
counted for each treatment. The number of cells in the
field of vision was multiplied to reflect the total cell
number on the 8 mm2 membrane.
Statistical analysis
One-way analysis of variance (ANOVA) with Dunnett's
multiple comparison post test correction was used for
multiple comparisons. Student's t-test was used for single
comparisons.
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